Latest Articlesddd
At the 60th American Society of Hematology (ASH) Annual Meeting CAR T is Still a Star With …
Prohost Letter #425 When Common Sense Fails to Explain the Market Performance It is not unusual …
Celyad (CYAD) is still a clinical-stage biopharmaceutical company developing advanced or improved CAR-T cell-based therapies. Today, …
Vertex Pharmaceuticals’ triple combination, which added the corrector VX-659 to the tezacaftor and ivacaftor combination, resulted …
As we expected in our posting yesterday under Today’s Highlights, the U.S. Food and Drug Administration (FDA) …
We hope you all took advantage of the Thanksgiving holiday to rest and relax. We did. …
This is just to inform that Europe has approved Cabometyx® (cabozantinib) tablets as a monotherapy for hepatocellular …
Aimmune Therapeutics (AIMT) has news. A lot of it is from a successful phase 3 trial …
The Week in Review #34 Improving on Immunotherapy and preventing one of its serious side effects. …
The Week in Review, which we will post soon, is going to provide news that cancer …
In today’s news Jazz Pharmaceuticals (JAZZ) announced the submission of a Marketing Authorization Application (MAA) to the European …
Yesterday, the Stock Market skyrocketed and with it a significant number of Prohost Picks that we …
RegenxBio (RGNX) has granted Abeona Therapeutics (ABEO) an exclusive worldwide license to its NAV AAV9 viral vector (subject …
Illumina (ILMN) and Pacific Biosciences (PACB) announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a …
Exelixis (EXEL) provided an update that testified to its solid fundamentals, the growth of its approved …
Celyad (CYAD) announced an exclusive agreement with Horizon Discovery Group plc, for the use of its shRNA …
A number of biotech or biopharmaceutical companies have succeeded in the past couple of years in …
The Week in Review #33 WE CALL IT THE BAD MARKET The Federal Reserve’s raising of …
Although the tests are for the prevention of a life-threatening metabolic disorder, the prenatal animal testing …
Tanezumab, an investigational humanized monoclonal antibody developed by Pfizer (PFE) and Eli Lilly (LLY), met all …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
